|
Collaborative, Licensing and Other Arrangements (Details)
Share data in Millions, except Per Share data, unless otherwise specified |
12 Months Ended | 36 Months Ended | 12 Months Ended | 12 Months Ended | 12 Months Ended | 12 Months Ended | 1 Months Ended | 12 Months Ended | 3 Months Ended | 1 Months Ended | 12 Months Ended | 1 Months Ended | 12 Months Ended | 1 Months Ended | 3 Months Ended | 1 Months Ended | 3 Months Ended | 1 Months Ended | 1 Months Ended | 12 Months Ended | 3 Months Ended | 12 Months Ended | ||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Dec. 31, 2012
USD ($)
|
Dec. 31, 2011
USD ($)
|
Dec. 31, 2010
USD ($)
|
Dec. 31, 2012
|
Dec. 31, 2003
USD ($)
|
Dec. 31, 2012
License Arrangement [Member]
|
Dec. 31, 2011
Servier [Member]
Up-front Payment Arrangement [Member]
USD ($)
|
Dec. 31, 2012
National Institute of Allergy and Infectious Diseases "NIAID" [Member]
Arrangement with Governmental Agency 1 [Member]
USD ($)
|
Dec. 31, 2011
National Institute of Allergy and Infectious Diseases "NIAID" [Member]
Arrangement with Governmental Agency 1 [Member]
USD ($)
|
Oct. 31, 2011
National Institute of Allergy and Infectious Diseases "NIAID" [Member]
Arrangement with Governmental Agency 1 [Member]
USD ($)
|
Dec. 31, 2012
National Institute of Allergy and Infectious Diseases "NIAID" [Member]
Arrangement with Governmental Agency 2 [Member]
USD ($)
|
Dec. 31, 2011
National Institute of Allergy and Infectious Diseases "NIAID" [Member]
Arrangement with Governmental Agency 2 [Member]
USD ($)
|
Dec. 31, 2010
National Institute of Allergy and Infectious Diseases "NIAID" [Member]
Arrangement with Governmental Agency 2 [Member]
USD ($)
|
Dec. 31, 2009
National Institute of Allergy and Infectious Diseases "NIAID" [Member]
Arrangement with Governmental Agency 2 [Member]
USD ($)
|
Sep. 30, 2008
National Institute of Allergy and Infectious Diseases "NIAID" [Member]
Arrangement with Governmental Agency 2 [Member]
USD ($)
|
Dec. 31, 2012
National Institute of Allergy and Infectious Diseases "NIAID" [Member]
Arrangement with Governmental Agency 3 [Member]
USD ($)
|
Jul. 31, 2006
National Institute of Allergy and Infectious Diseases "NIAID" [Member]
Arrangement with Governmental Agency 3 [Member]
USD ($)
|
Dec. 31, 2007
Pfizer Inc. [Member]
License Arrangement [Member]
USD ($)
|
Jan. 31, 2011
Collaborative Arrangement [Member]
Servier [Member]
USD ($)
|
Jan. 31, 2011
Collaborative Arrangement [Member]
Servier [Member]
EUR (€)
|
Dec. 31, 2012
Collaborative Arrangement [Member]
Servier [Member]
USD ($)
|
Dec. 31, 2011
Collaborative Arrangement [Member]
Servier [Member]
USD ($)
|
Dec. 31, 2012
Collaborative Arrangement [Member]
Servier [Member]
Sales And Development Milestones [Member]
USD ($)
|
Dec. 31, 2010
Collaborative Arrangement [Member]
Servier [Member]
Up-front Payment Arrangement [Member]
USD ($)
|
Sep. 30, 2010
Collaborative Arrangement [Member]
Servier - U.S. Perindopril Franchise [Member]
USD ($)
|
Dec. 31, 2012
Collaborative Arrangement [Member]
Servier - U.S. Perindopril Franchise [Member]
|
Dec. 31, 2012
Collaborative Arrangement [Member]
Servier - U.S. Perindopril Franchise [Member]
Development Milestone [Member]
USD ($)
|
Dec. 31, 2012
Collaborative Arrangement [Member]
Servier - U.S. Perindopril Franchise [Member]
Sales Milestone [Member]
USD ($)
|
Feb. 28, 2009
Collaborative Arrangement [Member]
Takeda [Member]
|
Nov. 30, 2006
Collaborative Arrangement [Member]
Takeda [Member]
|
Dec. 31, 2012
Collaborative Arrangement [Member]
Takeda [Member]
USD ($)
|
Dec. 31, 2011
Collaborative Arrangement [Member]
Takeda [Member]
USD ($)
|
Dec. 31, 2010
Collaborative Arrangement [Member]
Takeda [Member]
USD ($)
|
Dec. 31, 2012
Collaborative Arrangement [Member]
Takeda [Member]
Development Milestone [Member]
USD ($)
|
Feb. 28, 2009
Collaborative Arrangement [Member]
Takeda [Member]
Sales Milestone [Member]
USD ($)
|
Nov. 30, 2006
Collaborative Arrangement [Member]
Takeda [Member]
Sales Milestone [Member]
USD ($)
|
Nov. 30, 2008
Collaborative Arrangement [Member]
Novartis [Member]
USD ($)
|
Dec. 31, 2012
Collaborative Arrangement [Member]
Novartis [Member]
USD ($)
|
Nov. 30, 2008
Collaborative Arrangement [Member]
Novartis [Member]
Development Milestone [Member]
USD ($)
|
Sep. 30, 2009
Collaborative Arrangement [Member]
Arana Therapeutics Limited [Member]
USD ($)
|
Sep. 30, 2010
Collaborative Arrangement [Member]
Arana Therapeutics Limited [Member]
USD ($)
|
Sep. 30, 2009
Collaborative Arrangement [Member]
Arana Therapeutics Limited [Member]
USD ($)
|
Sep. 30, 2009
Collaborative Arrangement [Member]
Arana Therapeutics Limited [Member]
Sales Milestone [Member]
USD ($)
|
Oct. 31, 2009
Collaborative Arrangement [Member]
The Chemo-Sero-Therapeutic Research Institute "Kaketsuken" [Member]
USD ($)
|
Dec. 31, 2010
Collaborative Arrangement [Member]
The Chemo-Sero-Therapeutic Research Institute "Kaketsuken" [Member]
USD ($)
|
Dec. 31, 2009
Collaborative Arrangement [Member]
The Chemo-Sero-Therapeutic Research Institute "Kaketsuken" [Member]
USD ($)
|
Oct. 31, 2009
Collaborative Arrangement [Member]
The Chemo-Sero-Therapeutic Research Institute "Kaketsuken" [Member]
Sales Milestone [Member]
USD ($)
|
Mar. 31, 2003
Collaborative Arrangement [Member]
Genentech, Inc. ("Genentech") [Member]
|
Oct. 31, 2003
Collaborative Arrangement [Member]
Genentech, Inc. ("Genentech") [Member]
Convertible Preferred Stock [Member]
USD ($)
|
Oct. 31, 2003
Collaborative Arrangement [Member]
Genentech, Inc. ("Genentech") [Member]
Common Stock [Member]
USD ($)
|
Dec. 31, 2012
Collaborative Arrangement [Member]
Pfizer Inc. [Member]
Sales Milestone [Member]
USD ($)
|
Sep. 30, 2006
Non-arrangement Transactions [Member]
AVEO Pharmaceuticals, Inc. ("AVEO") [Member]
|
Apr. 30, 2006
Non-arrangement Transactions [Member]
AVEO Pharmaceuticals, Inc. ("AVEO") [Member]
|
Dec. 31, 2012
Non-arrangement Transactions [Member]
AVEO Pharmaceuticals, Inc. ("AVEO") [Member]
USD ($)
|
Dec. 31, 2011
Non-arrangement Transactions [Member]
AVEO Pharmaceuticals, Inc. ("AVEO") [Member]
USD ($)
|
Dec. 31, 2010
Non-arrangement Transactions [Member]
AVEO Pharmaceuticals, Inc. ("AVEO") [Member]
USD ($)
|
Sep. 30, 2006
Non-arrangement Transactions [Member]
AVEO Pharmaceuticals, Inc. ("AVEO") [Member]
Sales Milestone [Member]
USD ($)
|
Sep. 30, 2010
Non-arrangement Transactions [Member]
UCB Celltech [Member]
USD ($)
|
Dec. 31, 2010
Non-arrangement Transactions [Member]
UCB Celltech [Member]
USD ($)
|
Dec. 31, 2011
Non-arrangement Transactions [Member]
Pfizer Inc. [Member]
Development Milestone [Member]
USD ($)
|
|
| Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Deferred revenue, current | $ 15,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Non-refundable upfront payment received | 15,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Period for recognizing deferred revenue | 8 months | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Proceeds from loan | 19,500,000 | 15,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Total contract amount awarded | 28,000,000 | 64,800,000 | 16,300,000 | 6,000,000 | 6,000,000 | 8,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Contractual term | 5 years | 3 years | 3 years | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Increase in deferred revenue | 900,000 | 1,400,000 | 2,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Recognition of deferred revenue | 14,900,000 | 2,500,000 | 100,000 | 6,600,000 | 18,600,000 | 21,200,000 | 2,000,000 | 1,200,000 | 2,000,000 | 3,600,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||
| Future initial research and development expenses to be funded by counterparty | 50,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Future other expenses to be funded by counterparty (in hundredths) | 50.00% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Licensing and collaboration agreement revenue | 5,727,000 | 17,991,000 | 2,182,000 | 14,500,000 | 34,200,000 | 100,000 | 100,000 | 900,000 | 4,200,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||
| Future milestone payments, maximum | 470,000,000 | 3,250,000 | 19,000,000 | 14,000,000 | 3,000,000 | 200,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Future milestone payments, repurchase option not exercised, maximum | 810,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Number of fixed-dose combination product candidates included in a portfolio of antihypertensive products from Servier | 3 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| License fees paid | 1,500,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Amount due upon achievement of milestone | 8,500,000 | 15,100,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Future milestone payments with each additional future qualifying product candidate development, maximum | 20,750,000 | 1,700,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Royalty right expiration period | 10 years | 13 years 6 months | 20 years | 5 years | 15 years | 15 years | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Proceeds from collaborators | 6,200,000 | 2,000,000 | 4,000,000 | 2,000,000 | 6,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Reduction in debt under restructured agreement | 7,500,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Number of ongoing product programs with potential royalty right milestone payments | 2 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Maximum borrowing capacity under agreement | 50,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Research and development expenses funded through loan facility, maximum (in hundredths) | 75.00% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Number of versions of original AV-299 created | 4 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Additional future milestone payments | 8,300,000 | 6,300,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Proceeds from sale of royalty interest | 4,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Eligible share of operating profits and losses (in hundredths) | 25.00% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Repayment of loan | 29,600,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Number of shares of common stock issuable upon conversion (in shares) | 0.3 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Par value of common shares issuable upon conversion (in dollars per share) | $ 116.25 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Liquidation preference | 29,600,000 | 29,600,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Number of licenses granted, minimum | 60 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Proceeds from license fees received | $ 30,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Number of undisclosed product candidates with milestone payments received | 6 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||